Cargando…

Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer

Osimertinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), potently and selectively inhibits EGFR-TKI-sensitizing and EGFR T790M resistance mutations. In the Phase III FLAURA study (NCT02296125), first-line osimertinib improved outcomes vs comparator EGFR-TKIs in EGFRm ad...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chmielecki, Juliann, Gray, Jhanelle E., Cheng, Ying, Ohe, Yuichiro, Imamura, Fumio, Cho, Byoung Chul, Lin, Meng-Chih, Majem, Margarita, Shah, Riyaz, Rukazenkov, Yuri, Todd, Alexander, Markovets, Aleksandra, Barrett, J. Carl, Hartmaier, Ryan J., Ramalingam, Suresh S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9971254/ https://www.ncbi.nlm.nih.gov/pubmed/36849494 http://dx.doi.org/10.1038/s41467-023-35961-y

Ejemplares similares

Author Correction: Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer
por: Chmielecki, Juliann, et al.
Publicado: (2023)

Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial
por: Chmielecki, Juliann, et al.
Publicado: (2023)

Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset
por: Ohe, Yuichiro, et al.
Publicado: (2018)

Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers
por: Vaclova, Tereza, et al.
Publicado: (2021)

Combatting acquired resistance to osimertinib in EGFR-mutant lung cancer
por: Lee, Jiyun, et al.
Publicado: (2022)

Overcoming acquired resistance of EGFR‐mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol
por: Zang, Hongjing, et al.
Publicado: (2020)

Switching from first or second generation EGFR-TKI to osimertinib in EGFR mutation-positive NSCLC
por: Imamura, Fumio, et al.
Publicado: (2020)

Current treatment strategies for EGFR-mutated non-small cell lung cancer: from first line to beyond osimertinib resistance
por: Araki, Taisuke, et al.
Publicado: (2023)

Induction of BIM Is Essential for Apoptosis Triggered by EGFR Kinase Inhibitors in Mutant EGFR-Dependent Lung Adenocarcinomas
por: Gong, Yixuan, et al.
Publicado: (2007)

The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cells
por: Criscione, Steven W., et al.
Publicado: (2022)

Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, MET-Amplified Non–Small Cell Lung Cancer: TATTON
por: Hartmaier, Ryan J., et al.
Publicado: (2023)

Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer
por: Roper, Nitin, et al.
Publicado: (2020)

The ratio of T790M to EGFR-activating mutation predicts response of osimertinib in 1st or 2nd generation EGFR-TKI-refractory NSCLC
por: Tamiya, Motohiro, et al.
Publicado: (2021)

Response to ‘Clinical outcomes in NSCLC patients with EGFR mutations: pooled analysis’ (Paz-Ares et al., J Cell Mol Med. 2010; 14: 51–69)
por: Watkins, Claire, et al.
Publicado: (2010)

Cardiac Adverse Events in EGFR-Mutated Non-Small Cell Lung Cancer Treated With Osimertinib
por: Kunimasa, Kei, et al.
Publicado: (2020)

Survival benefit of combinatorial osimertinib rechallenge and entrectinib in an EGFR‐mutant NSCLC patient with acquired LMNA‐NTRK1 fusion following osimertinib resistance
por: Wang, Jiao‐Li, et al.
Publicado: (2022)

Brief Report: Heterogeneity of Acquired Resistance Mechanisms to Osimertinib and Savolitinib
por: Lim, Sun Min, et al.
Publicado: (2021)

The Third-Generation EGFR Inhibitor, Osimertinib, Promotes c-FLIP Degradation, Enhancing Apoptosis Including TRAIL-Induced Apoptosis in NSCLC Cells with Activating EGFR Mutations
por: Shi, Puyu, et al.
Publicado: (2019)

Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies
por: Hartmaier, Ryan J., et al.
Publicado: (2017)

Acquired EGFR C797S mediates resistance to AZD9291 in advanced non-small cell lung cancer harboring EGFR T790M
por: Thress, Kenneth S., et al.
Publicado: (2015)

Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study
por: Cheng, Ying, et al.
Publicado: (2021)

MERTK activation drives osimertinib resistance in EGFR-mutant non–small cell lung cancer
por: Yan, Dan, et al.
Publicado: (2022)

High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience
por: Piper-Vallillo, A.J., et al.
Publicado: (2022)

ALK rearrangements as mechanisms of acquired resistance to osimertinib in EGFR mutant non‐small cell lung cancer
por: Hou, Helei, et al.
Publicado: (2021)

Taking action early to manage emergence of acquired resistance to osimertinib or other third generation EGFR inhibitors
por: Ma, Guangzhi, et al.
Publicado: (2021)

Acquired BRAF gene fusions in Osimertinib resistant EGFR-mutant non-small cell lung cancer
por: Rosell, Rafael, et al.
Publicado: (2023)

Monitoring of Plasma EGFR Mutations during Osimertinib Treatment for NSCLC Patients with Acquired T790M Mutation
por: Watanabe, Kana, et al.
Publicado: (2023)

Molecular landscape of osimertinib resistance in patients and patient-derived preclinical models
por: Lim, Sun Min, et al.
Publicado: (2022)

Beneficial Effect of Osimertinib Readministration in Non-small-cell Lung Cancer Harboring an Epidermal Growth Factor Receptor (EGFR) Mutation with a History of Acquired Resistance to Osimertinib
por: Makimoto, Go, et al.
Publicado: (2019)

Osimertinib in Japanese patients with EGFR T790M mutation‐positive advanced non‐small‐cell lung cancer: AURA3 trial
por: Akamatsu, Hiroaki, et al.
Publicado: (2018)

Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-mutated Non-small Cell Lung Cancer
por: Lee, Jiyun, et al.
Publicado: (2019)

Acquired Resistance to Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer: How Do We Overcome It?
por: Bertoli, Elisa, et al.
Publicado: (2022)

Acquired Mechanisms of Resistance to Osimertinib—The Next Challenge
por: Ríos-Hoyo, Alejandro, et al.
Publicado: (2022)

Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma
por: Makhlin, Igor, et al.
Publicado: (2019)

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
por: Cui, Qingli, et al.
Publicado: (2022)

Acquired Concurrent EGFR T790M and Driver Gene Resistance From EGFR-TKIs Hampered Osimertinib Efficacy in Advanced Lung Adenocarcinoma: Case Reports
por: Zeng, Yue, et al.
Publicado: (2022)

Mixed response to osimertinib and the beneficial effects of additional local therapy
por: Shinno, Yuki, et al.
Publicado: (2019)

Primary resistance to osimertinib despite acquired T790M
por: Chang, Ling‐Kai, et al.
Publicado: (2020)

Comparison of clinical outcomes of osimertinib and first-generation EGFR-tyrosine kinase inhibitors (TKIs) in TKI-untreated EGFR-mutated non-small-cell lung cancer with leptomeningeal metastases
por: Tamura, K., et al.
Publicado: (2023)

EGFR G796D mutation mediates resistance to osimertinib
por: Zheng, Di, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_a95mj77dhucip91gd9as16p5f4